Lixisenatide (a new GLP-1 receptor agonist based on exendin-4) showed distinct pharmacological properties from liraglutide/exenatide: stronger post-meal glucose control with convenient once-daily dosing.
Key findingLixisenatide (a new GLP-1 receptor agonist based on exendin-4) showed distinct pharmacological properties from liraglutide/exenatide: stronger post-me
What the researchers found
Lixisenatide (a new GLP-1 receptor agonist based on exendin-4) showed distinct pharmacological properties from liraglutide/exenatide: stronger post-meal glucose control with convenient once-daily dosing.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2010.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes.
Regulatory peptides, 164(2-3), 58-64
Citation
Werner, Ulrich; Haschke, Guido; Herling, Andreas W; Kramer, Werner. (2010). Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes.. Regulatory peptides, 164(2-3), 58-64. https://doi.org/10.1016/j.regpep.2010.05.008